Latest Trials Latest NewsFAQ

WAKE FOREST UNIVERSITY HEALTH SCIENCES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

The Use of Biologic Mesh vs Bioabsorbable Mesh During Ventral Hernia Repair in At-risk Patients

Not Applicable

Terminated

Conditions: Ventral Hernia

Interventions: Device: Bio-A Arm
Device: Strattice Arm

First Posted Date: 2013-02-18

Last Posted Date: 2022-08-15

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 28

Registration Number: NCT01794338

Locations: 🇺🇸
Atrium Health - Carolinas Medical Center, Charlotte, North Carolina, United States

Bupivacaine for Benign Headache in the ED

Phase 2

Terminated

Conditions: Benign Headache

Interventions: Drug: 0.5% bupivacaine
Drug: Standard Care

First Posted Date: 2013-02-07

Last Posted Date: 2022-07-14

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 23

Registration Number: NCT01785459

Locations: 🇺🇸
Carolinas Medical Center, Charlotte, North Carolina, United States

Limb Girdle Muscular Dystrophy (LGMD) Natural History

Completed

Conditions: Muscular Dystrophies, Limb-Girdle (GENETICALLY CONFIRMED)

First Posted Date: 2013-02-05

Last Posted Date: 2022-04-28

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 13

Registration Number: NCT01783509

Locations: 🇺🇸
Carolinas Medical Center - Pediatrics, Charlotte, North Carolina, United States

Evaluating Sexual Function After Vaginal Repair With Perineorrhaphy

Not Applicable

Completed

Conditions: Sexual Function

Interventions: Procedure: Perineorrhaphy

First Posted Date: 2013-01-30

Last Posted Date: 2018-02-22

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 44

Registration Number: NCT01779739

Locations: 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Recurrent Adult Acute Myeloid Leukemia

Interventions: Drug: CPI-613
Drug: cytarabine
Drug: mitoxantrone hydrochloride
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2013-01-16

Last Posted Date: 2018-07-03

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 67

Registration Number: NCT01768897

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

Modified Barium Swallow in Measuring Swallowing Function After Surgery in Patients With Oropharyngeal Cancer

Not Applicable

Withdrawn

Conditions: Oropharyngeal Cancer

Interventions: Procedure: diagnostic imaging
Other: questionnaire administration
Procedure: quality-of-life assessment

First Posted Date: 2013-01-15

Last Posted Date: 2017-08-10

Lead Sponsor: Wake Forest University Health Sciences

Registration Number: NCT01767961

Cryosurgery and Radiation Therapy in Treating Patients With Painful Bone Metastases

Not Applicable

Terminated

Conditions: Pain
Bone Metastases

Interventions: Procedure: cryosurgery
Radiation: radiation therapy
Procedure: quality-of-life assessment

First Posted Date: 2013-01-15

Last Posted Date: 2018-11-14

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 1

Registration Number: NCT01767935

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery

Phase 1

Completed

Conditions: Recurrent Adult Primary Liver Cancer
Recurrent Extrahepatic Bile Duct Cancer
Adult Primary Cholangiocellular Carcinoma
Advanced Adult Primary Liver Cancer
Cholangiocarcinoma of the Extrahepatic Bile Duct
Unresectable Extrahepatic Bile Duct Cancer
Cholangiocarcinoma of the Gallbladder
Localized Unresectable Adult Primary Liver Cancer
Metastatic Extrahepatic Bile Duct Cancer

Interventions: Drug: 6,8-bis(benzylthio)octanoic acid

First Posted Date: 2013-01-11

Last Posted Date: 2019-05-15

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 17

Registration Number: NCT01766219

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

Prediction of Methotrexate Response - A Pilot Study

Completed

Conditions: Rheumatic Diseases
Rheumatoid Arthritis

First Posted Date: 2012-11-15

Last Posted Date: 2022-09-02

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 36

Registration Number: NCT01726959

Locations: 🇺🇸
Carolinas Medical Center - NorthEast, Concord, North Carolina, United States

Update and Biodistribution of [F-18]FMDHT pET/CT in Normal Healthy Volunteers and Patients With Metastatic Prostate Cancer - A First in Human Subject Study With [F-18] FMDHT

Early Phase 1

Terminated

Conditions: Prostate Cancer

Interventions: Drug: [F-18] fluorinated dihydrotestosterone (FDHT)

First Posted Date: 2012-11-12

Last Posted Date: 2018-07-03

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 7

Registration Number: NCT01724619

Locations: 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy